Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens Oliver Funk

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Neuroscience Research|March 3, 2004
Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's diseaseXiongwei Zhu, Andrew McShea, Peggy L R Harris, et al.
Molecular Cancer Therapeutics|October 6, 2017
The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug ClearanceEleni Venetsanakos, Ken A Brameld, Vernon T Phan, et al.
Journal of Medicinal Chemistry|July 1, 2017
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid TumorsKen A Brameld, Timothy D Owens, Erik Verner, et al.
The Journal of Biological Chemistry|January 17, 2015
Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694Yiming Zhong, Shuai Dong, Ethan Strattan, et al.
Nature Chemical Biology|May 26, 2015
Prolonged and tunable residence time using reversible covalent kinase inhibitorsJ Michael Bradshaw, Jesse M McFarland, Ville O Paavilainen, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Neuroscience Research|March 3, 2004
Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's diseaseXiongwei Zhu, Andrew McShea, Peggy L R Harris, et al.
Molecular Cancer Therapeutics|October 6, 2017
The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug ClearanceEleni Venetsanakos, Ken A Brameld, Vernon T Phan, et al.
Journal of Medicinal Chemistry|July 1, 2017
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid TumorsKen A Brameld, Timothy D Owens, Erik Verner, et al.
The Journal of Biological Chemistry|January 17, 2015
Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694Yiming Zhong, Shuai Dong, Ethan Strattan, et al.
Nature Chemical Biology|May 26, 2015
Prolonged and tunable residence time using reversible covalent kinase inhibitorsJ Michael Bradshaw, Jesse M McFarland, Ville O Paavilainen, et al.
Pageof 2